Skip to content
ppharmaranks
Menu
Class IIOngoing

Levothyroxine Sodium Tablets recall

FDA recall D-0259-2026 · initiated Dec 31, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jan 21, 2026How we research

Alvogen, Inc recalled Levothyroxine Sodium Tablets in Dec 2025 — an FDA Class II recall (D-0259-2026) because Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

Labelling, packaging or a product mix-up

The wrong information — or the wrong medicine — ended up in the pack. A mix-up is a manufacturing failure that can still be dangerous to swallow.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot # MHA21825, Exp Date: December 31, 2027

Details

Product
Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Manufactured by: LLOYD, Inc., Shenandoah, IA, 51601 USA, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC: 47781-662-10.
Recalling company
Alvogen Inc
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide.
Initiated
Dec 31, 2025
FDA report date
Jan 21, 2026

This recall is linked to a product we cover: Thyro-Tabs

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Levothyroxine Sodium Tablets recalled?
Alvogen, Inc recalled Levothyroxine Sodium Tablets in Dec 2025 — an FDA Class II recall (D-0259-2026) because Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Levothyroxine Sodium Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0259-2026 was: Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Is a recalled Levothyroxine Sodium Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Levothyroxine Sodium Tablets are affected?
Distributed: US Nationwide.. The recall covers these lots — Lot # MHA21825, Exp Date: December 31, 2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0259-2026.

Source: openFDA Drug Enforcement record D-0259-2026

← All drug recalls